Cargando…

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

Detalles Bibliográficos
Autores principales:	Arulananda, Surein, O’Brien, Megan, Evangelista, Marco, Harris, Tiffany J., Steinohrt, Nikita S., Jenkins, Laura J., Walkiewicz, Marzena, O’Donoghue, Robert J. J., Poh, Ashleigh R., Thapa, Bibhusal, Williams, David S., Leong, Trishe, Mariadason, John M., Li, Xia, Cebon, Jonathan, Lee, Erinna F., John, Thomas, Fairlie, W. Douglas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206255/ https://www.ncbi.nlm.nih.gov/pubmed/34131107 http://dx.doi.org/10.1038/s41420-020-00388-7

Ejemplares similares

BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2020)

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2021)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
por: Arulananda, Surein, et al.
Publicado: (2020)

Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report
por: Lie, Gabrielle, et al.
Publicado: (2020)

Uncommon EGFR-Mutant NSCLC—One Drug Does Not Fit All
por: Wang, Yang, et al.
Publicado: (2023)

Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells
por: Poh, Ashleigh R., et al.
Publicado: (2015)

Targeting H(i)ck education for cancer therapy?
por: Ernst, Matthias, et al.
Publicado: (2017)

Minimal residual disease in EGFR-mutant non-small-cell lung cancer
por: Bain, Nathan T., et al.
Publicado: (2022)

Induction of endoplasmic reticulum stress is associated with the anti‐tumor activity of monepantel across cancer types
por: Harris, Tiffany J., et al.
Publicado: (2023)

Mouse models for gastric cancer: Matching models to biological questions
por: Poh, Ashleigh R, et al.
Publicado: (2016)

The Structural Biology of Bcl-x(L)
por: Lee, Erinna F., et al.
Publicado: (2019)

Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers
por: Fairlie, W. Douglas, et al.
Publicado: (2021)

Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer
por: Fairlie, Walter Douglas, et al.
Publicado: (2021)

Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer
por: Lee, Erinna F., et al.
Publicado: (2021)

Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion
por: Zheng, Yuyan, et al.
Publicado: (2020)

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage
por: Seng, NS, et al.
Publicado: (2016)

Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy
por: Wang, Yang, et al.
Publicado: (2023)

Esophageal ‘pyocele’: thoracoscopic management
por: Sapkota, Ranjan, et al.
Publicado: (2019)

Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis
por: Zaman, Farzana Y., et al.
Publicado: (2023)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

Knockdown of Bcl-xL Enhances Growth-Inhibiting and Apoptosis-Inducing Effects of Resveratrol and Clofarabine in Malignant Mesothelioma H-2452 Cells
por: Lee, Yoon-Jin, et al.
Publicado: (2014)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

Structural biology of the intrinsic cell death pathway: what do we know and what is missing?
por: Lee, Erinna F., et al.
Publicado: (2012)

Adults, mathematics and work: from research into practice
por: Keogh, John J, et al.
Publicado: (2018)

Nutritional Regulators of Bcl-xL in the Brain
por: Park, Han-A, et al.
Publicado: (2018)

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
por: Shebl, Bassem, et al.
Publicado: (2022)

Retromer facilitates the localization of Bcl-xL to the mitochondrial outer membrane
por: Farmer, Trey, et al.
Publicado: (2019)

Effects of Cardiolipin on the Conformational Dynamics of Membrane-Anchored Bcl-xL
por: Tyagi, Vivek, et al.
Publicado: (2021)

Clinical neurologic indices of toxicity in animals.
por: O'Donoghue, J L
Publicado: (1996)

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review
por: Bi, Huanhuan, et al.
Publicado: (2021)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

BECLIN1: Protein Structure, Function and Regulation
por: Tran, Sharon, et al.
Publicado: (2021)

Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax
por: Billen, Lieven P, et al.
Publicado: (2008)

Bcl-xL as a Modulator of Senescence and Aging
por: Mas-Bargues, Cristina, et al.
Publicado: (2021)

Bcl-xL: A Focus on Melanoma Pathobiology
por: Lucianò, Anna Maria, et al.
Publicado: (2021)

Involvement of Bcl-xL in Neuronal Function and Development
por: Bas, Julie, et al.
Publicado: (2021)

The Role of Bcl-xL Protein in Viral Infections
por: Wyżewski, Zbigniew, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3lk9dev79t0oa4c8os61463u7r